A new frontier
in weight management
Science
goes further.
SERENOVO provides access to investigational Retatrutide, a next-generation, triple-receptor peptide, through a medically supervised program.
Retatrutide is investigational. Access is subject to regulatory requirements, clinical oversight, and individual eligibility.

A triple-pathway hypothesis.
Retatrutide is an investigational triple-receptor agonist being studied for weight management. It is designed to activate GLP-1, GIP and glucagon receptors—pathways involved in appetite, glucose metabolism and energy balance.
Results shown are from the 12 mg group in a published 48-week Phase 2 obesity trial. Individual outcomes vary. Read the peer-reviewed paper
Ongoing research: Retatrutide remains investigational and additional Phase 3 studies continue. View registered trials
Progress,
illustrated.
Fictional paired profiles help visualize a supported weight-management journey. They are not patient results or predictions.

I used to offer to take the photo so I wouldn't have to be in it. Now I'm trying to be in the memories, too.

I kept putting myself last. Making time for my health feels like showing up for my family, too.

Between work and the kids, I'd stopped checking in with myself. Making a little room for me matters, too.

I don't need a perfect week. I need a routine I can come back to when life gets messy.

Getting dressed used to mean trying on five outfits. I want my mornings back, without being so hard on myself.

I thought I had to figure it all out alone. Being able to ask questions makes the whole thing feel less heavy.
A considered path.
Clinical review first.
Explore two prototype support plans. This interface is illustrative and is not an offer to purchase or obtain Retatrutide.
Monthly support includes
A recurring care-pathway preview.
Monthly review pathway Ongoing clinician check-ins Cancel future plan anytimeIllustrative pricing only. Payment does not guarantee access; professional and regulatory review would be required.
Review your plan
Choose an available option to continue. Customer details, delivery, applicable taxes and payment are completed securely at checkout.
Your order
- No plan selected
- —
Purchasing is not currently available.
Payment does not guarantee clinical eligibility or access to investigational therapy.
Real science.
Real progress.
Retatrutide is being studied for how triple-receptor activity may influence appetite, metabolism, and energy balance.
- 1
Get ready
Review your study team's instructions and get your pen and supplies ready.
Check everything first. Your team can answer questions before you begin.
- 2
Choose your spot
Choose and prepare the area recommended by your study team.
Confirm the location, then follow the pen instructions your team provided.
- 3
Inject with ease
Follow the pen demonstration from your study team, at your own pace.
Your team explains what to check afterward and how to dispose of supplies.
- 4
Stay on track
Record your scheduled use and questions ahead of your next check-in.
Share how you feel so your team can review the next steps with you.
These images and steps are illustrative and are not instructions for use. Trial participants should follow their study team’s directions.
The essential
context.
Measured answers for an investigational therapy and a prototype experience.
Buy Now


